EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Could calcitonin gene‐related peptide inhibitors prevent status epilepticus?

Michael Nsaka iD, Noor Baban, Sepideh Allahdadian, Armin Scheffler iD, Diana Lindner, Dagny Holle iD, Alain Lekoubou iD

Epilepsia · 2026

DOI: 10.1002/epi.70436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2026. Verfasst von Michael Nsaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania, USA. Hauptthemen laut MEDLINE: Status Epilepticus, Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calcitonin gene‐related peptide (CGRP) inhibitors modulate pain and neuroinflammation, a recognized contributor to epileptogenesis and status epilepticus (SE). We examined the association between CGRP inhibitor use and SE hospitalization in epilepsy patients with comorbid migraine. Using TriNetX (130 healthcare organizations), we identified patients with epilepsy from May 2018 through May 2026, and propensity‐matched cohorts for age, sex, race, anti‐seizure medications (ASMs), migraine diagnosis, migraine treatments, and cognitive impairment. The primary outcome was SE occurrence. Following matching, 17 738 patients were on CGRP inhibitors and 18 594 were not. SE occurred in 427 (2.41%) and 860 (4.63%) patients, respectively. Mean age (±SD) was 48.4 ± 14.9 vs 48.9 ± 17.0 years. Risk difference was −2.2% (95% confidence interval [CI]: −2.6% to −1.8%, p < .001), risk ratio 0.52 (95% CI: 0.46–0.58), and odds ratio 0.51 (95% CI: 0.45–0.57). SE‐related hospital visits were significantly fewer in the CGRP inhibitor group ( t = −6.60, p < .001). CGRP inhibitor use was associated with reduced SE occurrence and hospitalization, supporting further investigation in patients with comorbid migraine and epilepsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Status EpilepticusCalcitonin Gene-Related PeptideMigraine DisordersHumansFemaleMaleMiddle AgedAdultAnticonvulsantsEpilepsyHospitalization

Stichwörter der Autor:innen

CGRP inhibitorsepilepsymigraineneuroinflammationstatus epilepticus

Substanzen

Calcitonin Gene-Related PeptideAnticonvulsants

Autor:innen und Institutionen

  • Department of Neurology, Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania, USA.
  • Department of Neurology and Centre for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Public Health Sciences, A210, Penn State College of Medicine, Hershey, Pennsylvania, USA.

ORCID-Profile: Michael Nsaka, Armin Scheffler, Dagny Holle, Alain Lekoubou

Zitieren

APA

Nsaka, M., Baban, N., Allahdadian, S., Scheffler, A., Lindner, D., Holle, D., & Lekoubou, A. (2026). Could calcitonin gene‐related peptide inhibitors prevent status epilepticus?. Epilepsia. https://doi.org/10.1002/epi.70436

Vancouver

Nsaka M, Baban N, Allahdadian S, Scheffler A, Lindner D, Holle D, et al. Could calcitonin gene‐related peptide inhibitors prevent status epilepticus?. Epilepsia. 2026. doi:10.1002/epi.70436

BibTeX
@article{Nsaka2026,
  author = {Nsaka, Michael and Baban, Noor and Allahdadian, Sepideh and Scheffler, Armin and Lindner, Diana and Holle, Dagny and Lekoubou, Alain},
  title = {Could calcitonin gene‐related peptide inhibitors prevent status epilepticus?},
  journal = {Epilepsia},
  year = {2026},
  doi = {10.1002/epi.70436}
}
Kostenlos starten →